New England-AACE 9th Annual Meeting

Newton, MA US
October 14, 2017

Welcome, and thank you for attending the New England Chapter of AACE 9th Annual Meeting.

The New England Chapter of AACE program committee has worked very hard to provide a relevant activity for the practicing clinical physician and other healthcare providers seeking education with an emphasis in endocrine disease.

This program has been planned to provide pertinent scientific and clinical information to help you achieve the best solutions in the diagnosis and therapeutic management of patients presenting with endocrine disease. Attendees will obtain updates in not only common and uncommon endocrine disorders, but also newer treatment modalities.

Providing exceptional patient care requires continuing high quality education. The American Association of Clinical Endocrinologists (AACE) was founded in 1991 by a visionary group of leaders to serve as the active voice for clinical endocrinologists. The impetus behind AACE's efforts has always been quality and cost-effective patient care for those with endocrine diseases and disorders. We hope that you will find this program of great value to you in your practice.

Target Audience

Endocrinologists, MDs / DOs, advanced practice clinicians and other healthcare professionals interested, advanced practice clinicians and other healthcare professionals interested in the treatment of endocrine disease living or working in Connecticut, Massachusetts, Maine, New Hampshire, Rhode Island and Vermont

Learning Objectives

  1. After participating in a pre-meeting assessment tool, attendees will be able to recognize areas of potential shortcoming and strive to improve knowledge and consequential healthcare practices.
  2. Describe mechanism of action of the SGLT2 inhibitors in diabetes management
  3. Review clinical outcome trials to date using this glucose lowering drug category
  4. Discuss the major unknowns about the SGLT2 inhibitors - both regarding their benefits and risks
  5. Understand clinical and diagnostic approach in female 46, XY disorders of sex development
  6. Recognize  disparities between the clinical presentation and the laboratory  findings
  7. Evaluate situations where thyroid function tests  don’t seem to make sense
  8. Analyze clinical findings where understand pathophysiology will lead to the correct conclusions
  9. Describe the etiology/pathogenesis and histopathology of Paget's disease of bone
  10. Recognize the variety of clinical features exhibited by patients with the disease
  11. Understand the approach to diagnosis, indications for therapy, and current management
  12. Recognize the clinical features of patients with oncogenic osteomalacia
  13. Describe the role of FGF23 in the pathophysiology of oncogenic ostenomalacia
  14. Understand the approach to diagnosis and management options
  15. Describe the clinical features and evaluation of neuroendocrine tumors
  16. Identify options for treatment of carcinoid syndrome
  17. Identify treatment options for control of neuroendocrine tumor growth
  18. Recognize the rationale for closed-loop insulin delivery for optimal care of persons with type 1 diabetes
  19. Understand the pathways and spectrum of approaches that have been undertaken to automate insulin delivery
  20. Review the important clinical studies demonstrating progress towards a commercial closed-loop system
  21. Attendees will be able to measure learning that occurred that will enable the use of new healthcare techniques and practices and to review or confirm existing care modalities.
Additional information
Available for MOC Points?: 
No
Practice Area: 
Diabetes
Hypoglycemia
Obesity
General Endo
Course summary
Available credit: 
  • 5.25 AMA
  • 5.25 Attendance
Course opens: 
10/14/2017
Course expires: 
10/14/2018
Event starts: 
10/14/2017 - 7:30am
Event ends: 
10/14/2017 - 6:00pm
Cost:
$0.00

Program Agenda

* Please click the program's title to view each presentation.

7:30 - 8:30 AMRegistration and Breakfast
8:30 - 8:45 AMOpening Remarks and Pre Meeting Assessment
Objectives:
  1. After participating in a pre-meeting assessment tool, attendees will be able to recognize areas of potential shortcoming and strive to improve knowledge and consequential healthcare practices.
8:45 - 9:35 AMSGLT2 Inhibitors: What we don't know and when will we know it?
Silvio Inzucchi, MD
Objectives:
  1. Describe mechanism of action of the SGLT2 inhibitors in diabetes management
  2. Review clinical outcome trials to date using this glucose lowering drug category
  3. Discuss the major unknowns about the SGLT2 inhibitors - both regarding their benefits and risks
9:35 - 9:55 AMFellow Presentation I: When Testes Make No Testosterone: Identifying a rare cause of 46, XY female phenotype in adulthood
Sira Korpaisarn, MD
Objectives:
  1. Understand clinical and diagnostic approach in female 46, XY disorders of sex development
9:55 - 10:25 AMBreak
10:25 - 11:15 AMThyroid Problems, Puzzles and Pearls
Gilbert H. Daniels, MD
Objectives:
  1. Recognize disparities between the clinical presentation and the laboratory findings
  2. Evaluate situations where thyroid function tests don’t seem to make sense
  3. Analyze clinical findings where understand pathophysiology will lead to the correct conclusions
11:15 - 12:05 PMPaget's Disease of Bone and Current Management
Joseph Tucci, MD, FACP, FACE
Objectives:
  1. Describe the etiology/pathogenesis and histopathology of Paget's disease of bone
  2. Recognize the variety of clinical features exhibited by patients with the disease
  3. Understand the approach to diagnosis, indications for therapy, and current management
12:05 - 1:30 PMBusiness Meeting/Lunch
12:05 - 12:45 PMPD Meeting
1:30 - 1:50 PMFellow Presentation II: Oncogenic Osteomalacia: The search, the treatment, and the cure of a debilitating tumor
Christopher W. Lee, MD
Objectives:
  1. Recognize the clinical features of patients with oncogenic osteomalacia
  2. Describe the role of FGF23 in the pathophysiology of oncogenic ostenomalacia
  3. Understand the approach to diagnosis and management options
1:50 - 2:40 PMEvaluation and Treatment of Neuroendocrine Malignancies
Jennifer Chan, MD, MPH
Objectives:
  1. Describe the clinical features and evaluation of neuroendocrine tumors
  2. Identify options for treatment of carcinoid syndrome
  3. Identify treatment options for control of neuroendocrine tumor growth
2:40 - 3:30 PMClosing the Loop for Type 1 Diabetes: Finally!
Stuart Weinzimer, MD
Objectives:
  1. Recognize the rationale for closed-loop insulin delivery for optimal care of persons with type 1 diabetes
  2. Understand the pathways and spectrum of approaches that have been undertaken to automate insulin delivery
  3. Review the important clinical studies demonstrating progress towards a commercial closed-loop system
3:30 - 3:45 PMPost Meeting Assessment, Closing Announcements and Adjournment
Objectives:
  1. Attendees will be able to measure learning that occurred that will enable the use of new healthcare techniques and practices and to review or confirm existing care modalities.
4:00 - 6:00 PMFellows Program (Non-CME)
Boston Marriott Newton
2345 Commonwealth Ave
Newton, MA 02459
United States

Jennifer Chan, MD, MPH

Assistant Professor of Medicine

Clinical Director, Neuroendocrine and Carcinoid Tumor Program

Dana-Farber Cancer Institute

Boston, MA

Gilbert H. Daniels, MD

Professor of Medicine Harvard School

James Howard Means Endowed Chair in Thyroid Disease, Co-Director thyroid Associates

Medical Director Endocrine Tumor Center at Massachusetts General Hospital

Boston, MA

Silvio Inzucchi, MD

Professor of Medicine

Yale University School of Medicine

Clinical Chief, Endocrinology

Director, Yale Diabetes Center

New Haven, CT

Sira Korpaisarn, MD

Endocrinology Fellow

Boston Medical Center

Section of Endocrinology, Diabetes, Nutrition and Weight Management

Boston, MA

Christopher W. Lee, MD

Endocrinology Fellow

Boston University School of Medicine

Boston Medical Center

Department of Medicine

Section of Endocrinology, Diabetes, and Nutrition

Boston, MA

Joseph R. Tucci, MD, FACP, FACE

Director, Division of Endocrinology & Metabolism

Roger Williams Medical Center

Professor of Medicine

Boston University School of Medicine

Boston, MA

Adjunct Professor of Medicine

The Warren Alpert School of Medicine at Brown University

Providence, RI

Stuart A Weinzimer, MD

Professor of Pediatrics

Yale University School of Medicine

New Haven, CT

The American Association of Clinical Endocrinologists (AACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association of Clinical Endocrinologists (AACE) designates this live activity for a maximum of 5.25 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 5.25 AMA
  • 5.25 Attendance

Accreditation Period

Course opens: 
10/14/2017
Course expires: 
10/14/2018

Price

Cost:
$0.00
Please login or register to take this course.